Aspen Neuroscience, a pioneering force in regenerative medicine, has received clearance from the U.S. FDA for its Investigational New Drug (IND) application for ANPD001. ANPD001 is a novel autologous (“self-derived”) cell therapy that has the potential to treat Parkinson’s Disease by replenishing lost dopamine neurons. This green light from the FDA propels Aspen Neuroscience into historic territory, initiating a clinical trial for ANPD001 in human patients. [Read more…]
Levels of Repair Inducible with Induced Pluripotent Stem Cells (iPS Cells)
Induced pluripotent stem cells can be strategically utilized at several biological levels, as described below. [Read more…]
ORIG3N, Producing Patient-Specific iPS Cells – Interview with Robin Smith, CEO
ORIG3N, a biotechnology start-up headquartered in Boston, is attracting global attention for several reasons. First, it has created the world’s largest blood cell repository. ORIG3N is using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs), allowing the cells to be ever-renewing and giving rise to a living database of humanity known as LifeCapsule.
Second, the company has two other business segments, called LifeProfile and LifeSystems. These business units of ORIG3N help people to better understand the links between their genes and how their minds and bodies work.
Third, ORIG3N has identified HLA Superdonor matches for 90% of the U.S. population, positioning it to be custodians of this “first of a kind asset on planet earth.”
Vita Therapeutics Receives Orphan Drug Designation from FDA for Allogenic iPSC-based Therapy
BALTIMORE, July 23, 2020 — Vita Therapeutics, Inc. has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for VTA-110, a novel regenerative therapy for the treatment of Duchenne’s Muscular Dystrophy (DMD).
VTA-110, is a potential first-in-class allogenic iPSC-based therapy that has shown the ability to repair and regenerate healthy muscle in preclinical studies and has the potential to benefit patients with DMD. [Read more…]
Platelet BioGenesis Bags $56M to Develop Human iPSC-Derived Platelets as Nuclear Countermeasure
Highlights:Â
- Platelet BioGenesis has the world’s first technology to generate clinical-grade human platelets from induced pluripotent stem cells (iPSCs).
- Platelet BioGenesis has been awarded $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop donor-independent platelets as a treatment for radiological and nuclear exposure.
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 18
- Next Page »